Dr. Patrick McNutt is an Associate Professor at the Wake Forest Institute for Regenerative Medicine (WFIRM) in the Wake Forest University School of Medicine, with a secondary appointment in the Department of Microbiology and Immunology. His research focuses on understanding and treating the medical consequences of hazardous biological and chemical agents, using both translational animal models and advanced microphysiological models. Dr. McNutt completed his PhD studies in Molecular Biology at Princeton University under the guidance of Dr. Malcolm Steinberg. After serving a mandatory military service obligation, he accepted a position as a DOD researcher for 10 years before transitioning to an academic faculty position at WFIRM in 2020. He continued his military service in the US Army Reserve, retiring as a colonel in 2025. Dr. McNutt's lab is currently focused on three subject areas: developing novel treatments for neuromuscular paralysis due to biological toxins and autoimmune disorders; understanding the systemic effects of chemical vapor exposures; and developing next-generation microphysiological models. Dr. McNutt is also the director of an NIH-supported research facility that provides chemical exposure expertise to NIH-funded investigators within the Chemical Countermeasures Research Program. He has published over 70 peer-reviewed papers in various journals, contributed five book chapters, and holds four patents.
Dr. Patrick McNutt is an Associate Professor at the Wake Forest Institute for Regenerative Medicine (WFIRM) in the Wake Forest University School of Medicine, with a secondary appointment in the Department of Microbiology and Immunology. His research focuses on understanding and treating the medical consequences of hazardous biological and chemical agents, using both translational animal models and advanced microphysiological models. Dr. McNutt completed his PhD studies in Molecular Biology at Princeton University under the guidance of Dr. Malcolm Steinberg. After serving a mandatory military service obligation, he accepted a position as a DOD researcher for 10 years before transitioning to an academic faculty position at WFIRM in 2020. He continued his military service in the US Army Reserve, retiring as a colonel in 2025. Dr. McNutt's lab is currently focused on three subject areas: developing novel treatments for neuromuscular paralysis due to biological toxins and autoimmune disorders; understanding the systemic effects of chemical vapor exposures; and developing next-generation microphysiological models. Dr. McNutt is also the director of an NIH-supported research facility that provides chemical exposure expertise to NIH-funded investigators within the Chemical Countermeasures Research Program. He has published over 70 peer-reviewed papers in various journals, contributed five book chapters, and holds four patents.